Domestic manufacturing of critical injectables reduces exposure to supply chain disruptions that could result from trade policy changes, export controls, or quality failures at Chinese API manufacturers
Consistent with these findings, in STEP 5 semaglutide treatment improved a range of cardiometabolic risk parameters, including waist circumference, systolic and diastolic blood pressure, HbA 1c levels, total cholesterol, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol and triglycerides
42,47,49,50 Treatment Considerations for the Patient Taking a GLP-1 RA Given the multifaceted role of AT in tissue homeostasis, a comprehensive regenerative approach should be considered for patients experiencing GLP-1 RA-MWL, rather than an approach focused on volumetric correction
14% body weight regained within one year of stopping tirzepatide 14% body weight regained within one year of stopping tirzepatide Other reputable clinical studies have been consistent in finding that patients experience significant weight regain* when they discontinue these medications.* The drawbacks of a one-size-fits-all approach Programs that promote GLP-1 deprescribing often employ a one-size-fits-all strategy including the diet used as a part of their program
